Phase III trial of lenalidomide vs observation alone in pts with asymptomatic high-risk SMM

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk SMMПодробнее

ECOG-E3A06: lenalidomide vs. observation alone in SMMПодробнее

Evidence supporting lenalidomide for high-risk smoldering myeloma patientsПодробнее

Clinical Trials’ Impact on Smoldering Myeloma ManagementПодробнее

Dr. Mark Bustoros discusses clinical trial results for high-risk smoldering multiple myelomaПодробнее

Lenalidomide for smoldering myelomaПодробнее

Lenalidomide vs Observation for Asymptomatic High-Risk Smoldering Multiple MyelomaПодробнее

ITHACA trial results: combination of isatuximab, lenalidomide & dexamethasone for high-risk SMMПодробнее

Case 1: Patient with high-risk smoldering myelomaПодробнее

Update on recent smoldering multiple myeloma trialsПодробнее

Smoldering myeloma: Who and when to treat?Подробнее

Reducing SMM transformation risk: carfilzomib, lenalidomide & dexamethasoneПодробнее

Benefit of treating smouldering myeloma patients early with lenalidomide & dexamethasoneПодробнее

Dr. Sagar Lonial on Lenalidomide Versus Observation in Smoldering MyelomaПодробнее

Dr. Chari on the E3A06 Trial in Smoldering MyelomaПодробнее

Smoldering multiple myeloma: Early detection and intervention approaches by Dr. Mark BustorosПодробнее

Smoldering Myeloma: Who and when to treat?Подробнее

4-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and DexamethasoneПодробнее